Get startedLog in
    Picture of AstraZeneca logo

    AZN — AstraZeneca News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: CSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugs

    Picture of AstraZeneca logoAstraZeneca
    02/07/2026 09:35
    BRIEF-CSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugs
    July 2 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:
    • PHARMA ENTERS COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR SIRNA DRUGS
    • PHARMA RETAINS RIGHTS TO ONE PCC IN CHINA
    • ENTERING INTO COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR DEVELOPMENT OF SIRNA DRUGS
    • PHARMA TO RECEIVE $30 MILLION UPFRONT, UP TO $540 MILLION DEVELOPMENT AND $1.2 BILLION SALES MILESTONES
    • ASTRAZENECA HAS OPTION FOR EXCLUSIVE GLOBAL OR EX-CHINA RIGHTS FOR EACH PCC PROGRAM
    Further company coverage: 1093.HK

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on AstraZeneca

    See all news